Table of Contents
Section 1: General Human Research Protection Program Polices
1.1 Human Research Protection Program
1.3 UNMC Serving as Central IRB
1.4 UNMC Ceding Review to an External Central IRB
1.5 Requirements for Research Conducted at International Sites
1.6 IRB Composition, Leadership, Qualifications, & Responsibilities
1.7 IRB Member, Consultant, Staff COI Identification & Management
1.8 Investigational Activities Requiring IRB Review & Approval
1.9 Resources Necessary to Protect Subjects
1.10 Scientific and Other Committee Review of Research
1.11 HRPP Access to Legal Counsel
1.13 Compliance with ICH-GCP Guidelines
1.14 Research Subject to Department of Defense Regulatory Requirements
1.15 Research Subject to Department of Justice Regulatory Requirements
1.16 ORA Record Keeping Requirements
1.17 Retention of Research Records
1.18 Review and Approval of HRPP Policies and Procedures
1.20 Community Involvement in Research & Outreach Activities
1.21 Post-Approval Monitoring of Research
1.22 Assessment of the Effectiveness and Efficiency of the HRPP
1.23 HRPP Training Requirements and Opportunities for Research Personnel
1.24 HRPP Training Requirements for IRB Members
1.25 Financial Conflicts of Interest
1.26 PI Qualifications & Responsibilities
1.27 Research Personnel Qualifications and Responsibilities
1.28 External Investigator Assurance
1.29 ClinicalTrials.gov Reporting
1.30 Use of the Rapid Response IRB
1.31 Observers at IRB Meetings
1.32 Confidentiality of the Review Process
Section 2: Process of Review
2.1 Submission of Items for Review by the IRB
2.4 IRB Review of Changes in Previously Approved Research
2.7 Continuing Review of Research
2.9 Closure of On-Going Research
Section 3: Special Issues
3.2 Data and Safety Monitoring
3.3 Privacy Interests and Confidentiality of Research Data
3.4 Use of Protected Health Information in Research
3.5 Subject Recruitment Through Advertisements
3.6 Subject Recruitment Through Direct Invitation
3.7 Finder’s Fees and Recruitment Bonuses
3.8 Research Subject Compensation
3.9 Contraception Requirements
3.11 Collecting Data from Pregnant Partners of Research Subjects
3.13 Use of Placebo or Wash-Out of Effective Therapy in Clinical Trials
3.14 Phase I and First-in-Human Studies
3.15 Managing Radiographic Incidental Findings in Human Subjects Research
Section 4: Vulnerable Populations
4.1 Additional Protections for Vulnerable Populations
4.3 Research Involving Prisoners
4.4 Research Involving Children
4.5 Local 407 Panel Review of Pediatric Research
4.6 IRB Review of Research Involving Subjects with Impaired Decision-Making Capacity
4.7 Research Involving Employees of the Organization and Students as Subjects
Section 5: Informed Consent
5.1 Obtaining Informed Consent from Research Subjects
5.2 Waiver or Alteration of Informed Consent and HIPAA Authorization
5.3 Use of a Telephone Consent Process
5.4 Waiver of the Requirement to Obtain Signed Consent Form
5.5 Use of the Short Form Consent Document
5.6 Exception from Informed Consent Requirements for Emergency Research
Section 6: FDA Regulated Research/Drugs & Devices
6.1 Research Involving Investigational and Marketed Drugs
6.2 Research Involving Investigational and Marketed Devices
6.3 Humanitarian Use Device (HUD)
6.4 Emergency Use of a Test Article
Section 7: Human Biological Materials and Data Registries
7.1 Banking Human Biological Materials
7.2 Use of Human Biological Material in Research
Section 8: AEs, Unanticipated Problems and Compliance
8.1 IRB Review of Adverse Events and Adverse Device Effects
8.2 IRB Review of Study Related Complaints
8.3 IRB Review of Unanticipated Problems Involving Risk to the Subject or Others
8.4 Review of Noncompliance Involving the PI and Study Personnel
8.5 Noncompliance by the IRB or Other Components of the HRPP
8.6 Study Hold, Suspension, and Termination
8.7 Reporting Incidents to Institutional Officials and Federal Agencies